The measurable, persistent, low-grade level of inflammatory activity present throughout the body in the absence of acute infection or injury, often quantified by circulating biomarkers such as high-sensitivity C-reactive protein (hs-CRP) or interleukins. This elevated baseline is not clinically acute but represents a chronic, subclinical immunological stressor that drives insulin resistance, endothelial dysfunction, and hormonal dysregulation. Maintaining a low baseline is a key marker of metabolic health.
Origin
This term is derived from clinical immunology and endocrinology, recognizing that chronic, non-resolving inflammation is a core driver of non-communicable diseases. “Systemic” indicates the whole-body nature of the process, and “baseline” emphasizes the persistent, steady-state level of this activity. It links immune function directly to metabolic and hormonal health.
Mechanism
Adipose tissue dysfunction, particularly visceral fat accumulation, is a major source, releasing pro-inflammatory adipokines and cytokines that enter circulation. These inflammatory mediators interfere with insulin signaling pathways, promoting insulin resistance in muscle and liver cells. Chronic HPA axis overdrive and elevated cortisol can initially suppress inflammation but eventually lead to glucocorticoid resistance, further elevating the systemic baseline and accelerating metabolic and cardiovascular risk.
We use cookies to personalize content and marketing, and to analyze our traffic. This helps us maintain the quality of our free resources. manage your preferences below.
Detailed Cookie Preferences
This helps support our free resources through personalized marketing efforts and promotions.
Analytics cookies help us understand how visitors interact with our website, improving user experience and website performance.
Personalization cookies enable us to customize the content and features of our site based on your interactions, offering a more tailored experience.